Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: Founder and CEO,CSO
Company: Hua Medicine (Shanghai) Ltd.
个人简介:
Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer. leads Hua Medicine a clinical stage biotech company whose mission is to bring personalized diabetes medicines to patients in China and worldwide. He is a pioneer in collaborative innovation in China and advanced Hua Medicine with an operation principle of high standards, high quality and create high value. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Under his leadership, Hua Medicine completed successfully a POC study and initiated China NDA enabling process. During this period, Hua Medicine raised 200M USD and established the leading position of Hua Medicine in China biotech industry.Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 35 granted patents and an author with over 60 publications.
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: VP and Head of Global Research Beyond Borders
Company: Boehringer Ingelheim
个人简介:
Henri Doods received his PhD in Pharmacology at the University of Amsterdam. He joined Boehringer Ingelheim in 1987 and covered different positions within cardiovascular, pain, obesity, central nervous system and respiratory research. Currently, he heads the Global Department Research Beyond Borders with the responsibility to capture emerging science/new indications and novel technologies/modalities and is member of the Global Boehringer Ingelheim Discovery Research Leadership Committee. He is (co) author of more than 135 publications and was involved in progressing 15 compounds into development.
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: Partner
Company: Eight Roads Ventures
个人简介:
Dr. Will Liu is a Partner of Eight Roads Ventures China, specializing in healthcare investment with twenty years of experience in the pharmaceutical and biotech industries. Prior to joining Eight Roads, Will held several positions of business development in multinational pharmaceutical companies, including Head of Worldwide Business Development for Neurosciences at GSK and Head of External Innovation China at Merck KGaA. Will was trained as a scientist and worked in drug discovery for over ten years. Will graduated from Nankai University in China and received his Ph.D. degree from the University of Michigan.
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: CSO
Company: Livzon Pharmaceutical Group Inc.
个人简介:
Dr. Hong Wen has been a scientific lead and senior reviewer since joined FDA in 2013.  His review disciplines cover DMFs, ANDAs, NDAs, supplements, citizen petitions and controlled correspondences.  His research responsibilities focus on the impact of drug delivery on therapeutic performance of generic drug products, such as bioequivalence (BE) guidance development, ANDA reviews, and post-marketing investigations.  Prior to joining FDA in 2013, Hong has worked 11 years in pharmaceutical industry and has contributed to multiple IND/IMPD/NDA filings including nine NDA approvals. During his tenure in Novartis, he was project leader of multiple pharmaceutical development teams and a core member of Novartis TRD Science & Technology committee.  In 2002, he received his Ph.D. in Industrial and Physical Pharmacy from Purdue University. In April 2018, he joined Livzon Pharmaceuticals as Chief Scientific Officer.